NFL Biosciences SAS (ALNFL) - Total Liabilities
Based on the latest financial reports, NFL Biosciences SAS (ALNFL) has total liabilities worth €2.60 Million EUR (≈ $3.04 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NFL Biosciences SAS - Total Liabilities Trend (2018–2024)
This chart illustrates how NFL Biosciences SAS's total liabilities have evolved over time, based on quarterly financial data. See NFL Biosciences SAS short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
NFL Biosciences SAS Competitors by Total Liabilities
The table below lists competitors of NFL Biosciences SAS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
eEducation Albert AB
ST:ALBERT
|
Sweden | Skr99.54 Million |
|
Lepidico Ltd
AU:LPD
|
Australia | AU$13.55 Million |
|
Seamless Distribution Systems AB
ST:SDS
|
Sweden | Skr339.60 Million |
|
Jackpot Digital Inc
V:JJ
|
Canada | CA$13.28 Million |
|
PZ Cormay SA
WAR:CRM
|
Poland | zł35.71 Million |
|
CSH Alliance Bhd
KLSE:7165
|
Malaysia | RM15.99 Million |
|
UCrest Bhd
KLSE:0005
|
Malaysia | RM4.78 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down NFL Biosciences SAS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NFL Biosciences SAS market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NFL Biosciences SAS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NFL Biosciences SAS (2018–2024)
The table below shows the annual total liabilities of NFL Biosciences SAS from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.63 Million ≈ $3.08 Million |
-27.27% |
| 2023-12-31 | €3.62 Million ≈ $4.23 Million |
+133.37% |
| 2022-12-31 | €1.55 Million ≈ $1.81 Million |
+290.09% |
| 2021-12-31 | €397.73K ≈ $464.98K |
-6.77% |
| 2020-12-31 | €426.61K ≈ $498.76K |
+669.14% |
| 2019-12-31 | €55.47K ≈ $64.85K |
-70.62% |
| 2018-12-31 | €188.79K ≈ $220.71K |
-- |
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more